They want to capture part of a E100 million market with 20% growth expected.
Judy Ritchie
http://www.nutraingredients.com/news/ng.asp?n=64905&m=1NIE106&c=ymhgzhkpfeeb
tvm
Pharming takes step towards lactoferrin commercialisation
By Dominique Patton
History:
Pharming completes GRAS notification on human lactoferrin
Pharming reports on safety of human lactoferrin for food use
Pharming gets Japanese patent on human lactoferrin
Pharming licenses lactoferrin production tech to NZ group
Dutch group increases stake in lactoferrin producer
06/01/2006 - Dutch biotech group Pharming is stepping up talks with
nutritional companies in the US to bring its recombinant human lactoferrin
to the market, after submitting safety data to the Food and Drug
Administration.
-----
“We're talking to some manufacturers and nutritional companies in the US
about the possibilities of using it as a standalone product or an ingredient
in foods. A lot will depend on the partner, and relate to the end product.
It may require additional end studies, for example if it is used in infant
foods.”
---
The current market for bovine lactoferrin is thought to be worth around ˆ100
million per year, with growth of about 20 per cent, suggests Singh. The
majority of sales are in Asia where lactoferrin supplements are common and
dairy companies fortify yoghurts with the protein.
***********************************************
To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
